DPP-4 Inhibitor Therapy (Gliptins)

📖 Wiki Page

therapeutic1928 wordssynced 2026-04-02

DPP-4 Inhibitor Therapy (Gliptins)

...

DPP-4 Inhibitor Therapy (Gliptins)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">DPP-4 Inhibitor Therapy (Gliptins)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Current Position</td>
</tr>
<tr>
<td class="label">Regulatory status</td>
<td>Approved for type 2 diabetes (global)</td>
</tr>
<tr>
<td class="label">Neurodegeneration trials</td>
<td>Phase II/III ongoing for AD/PD</td>
</tr>
<tr>
<td class="label">Main evidence strength</td>
<td>Strong preclinical neuroprotection; mixed early clinical signals</td>
</tr>
<tr>
<td class="label">Key drugs</td>
<td>Sitagliptin, Saxagliptin, Linagliptin, Vildagliptin</td>
</tr>
<tr>
<td class="label">Major practical advantage</td>
<td>Oral administration, well-established safety in diabetes</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">NCT02953093</td>
<td>Sitagliptin</td>
</tr>
<tr>
<td class="label">NCT03431779</td>
<td>Linagliptin</td>
</tr>
<tr>
<td class="label">NCT05337635</td>
<td>Sitagliptin</td>
</tr>
<tr>
<td class="label">NCT05674282</td>
<td>Saxagliptin</td>
</tr>
<tr>
<td class="label">NCT05206168</td>
<td>Linagliptin</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Half-life</td>
</tr>
<tr>
<td class="label">Sitagliptin</td>
<td>12.4 h</td>
</tr>
<tr>
<td class="label">Saxagliptin</td>
<td>2.5 h (active metabolite 3.5 h)</td>
</tr>
<tr>
<td class="label">Linagliptin</td>
<td>12 h</td>
</tr>
<tr>
<td class="label">Vildagliptin</td>
<td>2-3 h</td>
</tr>
<tr>
<td class="label">Dimension</td>
<td>Score (0-10)</td>
</tr>
<tr>
<td class="label">Mechanistic Clarity</td>
<td>8</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>5</td>
</tr>
<tr>
<td class="label">Preclinical Evidence</td>
<td>9</td>
</tr>
<tr>
<td class="label">Replication</td>
<td>6</td>
</tr>
<tr>
<td class="label">Effect Size</td>
<td>5</td>
</tr>
<tr>
<td class="label">Safety/Tolerability</td>
<td>9</td>
</tr>
<tr>
<td class="label">Biological Plausibility</td>
<td>8</td>
</tr>
<tr>
<td class="label">Actionability</td>
<td>8</td>
</tr>
</table>

Overview

Dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins, are a class of oral antihyperglycemic agents originally developed for type 2 diabetes mellitus. These drugs inhibit the DPP-4 enzyme, which degrades incretin hormones including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By prolonging incretin activity, DPP-4 inhibitors enhance glucose-dependent insulin secretion and suppress glucagon release.[@drucker2006][@gallwitz2015]

Beyond their metabolic effects, DPP-4 inhibitors have attracted significant interest for [neurodegenerative disease](/diseases/neurodegeneration) therapy due to their neuroprotective, anti-inflammatory, and anti-apoptotic properties observed in preclinical models of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), [Parkinson's disease](/diseases/parkinsons-disease) (PD), and [amyotrophic lateral sclerosis](/diseases/als) (ALS).[@kosar2023][@zhang2021][@bellen2022] The ability of DPP-4 inhibitors to cross the [blood-brain barrier](/entities/blood-brain-barrier) and modulate neuroinflammation positions them as repurposing candidates for targeting multiple neurodegenerative pathways simultaneously.

Quick Clinical Snapshot

Mechanistic Rationale

DPP-4 Inhibition and GLP-1 Elevation

DPP-4 is a serine protease expressed widely in peripheral tissues and the [central nervous system](/cell-types/neurons). It exists in both membrane-bound and soluble forms, with the latter circulating in plasma and cerebrospinal fluid.[@deacon2020] By cleaving GLP-1 and GIP, DPP-4 limits their insulinotropic and neuroprotective effects. DPP-4 inhibition restores incretin activity, leading to enhanced [GLP-1 receptor](/proteins/glp1r) signaling in the brain.[@kosar2023]

[GLP-1 receptor](/entities/glp1-receptor) activation in [neurons](/entities/neurons) promotes:

Improved mitochondrial function and ATP production
Reduced oxidative stress through antioxidant enzyme upregulation
Inhibition of pro-apoptotic signaling cascades
Enhanced [autophagy](/entities/autophagy) and clearance of misfolded proteins
Neurogenesis and synaptic plasticity in hippocampal regions[@hlscher2020][@salcedo2019]

Anti-Inflammatory Effects

Chronic neuroinflammation is a hallmark of neurodegenerative diseases, characterized by microglial activation and elevated pro-inflammatory cytokines.[@kwon2020] DPP-4 inhibitors reduce neuroinflammation through multiple mechanisms:

Microglial polarization: Shifting from pro-inflammatory M1 to anti-inflammatory M2 phenotype

Cytokine suppression: Reducing TNF-α, IL-1β, and IL-6 levels in brain tissue

[NLRP3 inflammasome](/entities/nlrp3-inflammasome) inhibition: Blocking caspase-1 activation and downstream cytokine maturation

[NF-κB](/entities/nf-kb) pathway modulation: Attenuating this central inflammatory transcription factor[@damico2019][@rashid2022]

Direct DPP-4 Effects on Neural Cells

Beyond incretin-mediated effects, DPP-4 itself participates in immune regulation. DPP-4 (also known as CD26) is expressed on T lymphocytes and modulates T-cell activation and cytokine production.[@klemann2016] In the brain, DPP-4 activity influences:

Neuronal survival through substrate-specific signaling
Astrocyte inflammatory responses
Peripheral immune cell trafficking across the blood-brain barrier

Pathway Diagram

Mermaid diagram (expand to render)

Preclinical Evidence

Alzheimer's Disease Models

In various AD mouse models ([APP](/entities/app-protein)/PS1, 3xTg-AD, 5xFAD), DPP-4 inhibitors have demonstrated:

Amyloid pathology reduction: Decreased Aβ plaque burden and soluble Aβ levels in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex)[@jing2021][@chen2020]
[Tau](/proteins/tau) pathology modulation: Reduced phosphorylated tau levels and tau aggregation[@zhou2021]
Cognitive improvement: Enhanced performance in Morris water maze, novel object recognition, and Y-maze tests[@jing2021][@chen2020][@zhou2021]
Synaptic protection: Preserved synaptic markers (synaptophysin, PSD-95) and dendritic spine density[@wang2022]
Neurogenesis enhancement: Increased hippocampal neurogenesis in the subgranular zone[@li2019]

Parkinson's Disease Models

In rodent PD models (MPTP, 6-OHDA, α-synuclein transgenic):

Dopaminergic neuron protection: Reduced loss of [tyrosine hydroxylase](/proteins/tyrosine-hydroxylase)-positive neurons in substantia nigra pars compacta[@wang2020][@yang2021]
Behavioral improvement: Enhanced rotarod performance, reduced catalepsy, improved gait parameters[@wang2020][@yang2021]
α-synuclein modulation: Decreased α-synuclein aggregation and phosphorylation[@liu2022]
Mitochondrial protection: Improved complex I activity and ATP levels in dopaminergic neurons[@kim2021]
Neuroinflammation reduction: Lowered microglial activation and inflammatory markers in striatum and substantia nigra[@yang2021]

Amyotrophic Lateral Sclerosis Models

In SOD1-G93A transgenic mice (a genetic model of ALS):

Motor neuron survival: Delayed motor neuron loss and preserved spinal cord motor neuron counts[@zhang2020]
Functional improvement: Extended disease onset and improved Rotarod performance[@zhang2020]
Glial response modulation: Reduced astrocyte and microglial activation in spinal cord[@liu2021]
Muscle protection: Attenuated denervation and muscle atrophy[@zhang2020]

Clinical Evidence

Ongoing and Completed Trials

Sitagliptin in Alzheimer's Disease

The Phase II trial of sitagliptin in AD (NCT02953093) showed:

Acceptable safety and tolerability over 52 weeks
No significant cognitive decline in treatment group versus placebo (trend toward benefit)
Reduced progression in a subset with better baseline glycemic control[@trial2024]

Key limitations include small sample size and short duration for an AD trial.

Linagliptin in Parkinson's Disease

A 52-week Phase II trial of linagliptin in PD (NCT03431779) demonstrated:

Primary safety endpoint met
Signal suggesting slower UPDRS progression in treatment arm (post-hoc analysis)
Good tolerability with no hypoglycemia risk (linagliptin is renally excreted)[@linagliptin2023]

Safety Profile in Elderly Populations

DPP-4 inhibitors have a well-established safety record in older adults with diabetes:

Hypoglycemia risk: Low, as glucose-dependent mechanism preserves counterregulation
Pancreatitis: Rare but recognized risk; meta-analyses show slight increase versus placebo[@singh2011]
Joint pain: Class effect including severe arthralgia reported[@tarapues2013]
Skin reactions: Rare bullous pemphigoid cases reported[@anagnostou2021]
Cardiovascular safety: Cardiovascular outcome trials show neutral to favorable effects[@green2015]

For neurodegenerative disease populations, the oral route, lack of need for titration, and low hypoglycemia risk are practical advantages over injectable GLP-1 receptor agonists.

Pharmacokinetics and Dosing

Linagliptin's hepatic metabolism and fecal excretion make it preferred in patients with renal impairment—a common comorbidity in elderly neurodegenerative disease patients.[@graefemody2012]

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/als)
[GLP-1 Receptor Agonists](/therapeutics/glp1-receptor-agonists)
[Neuroinflammation](/mechanisms/neuroinflammation)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Alpha-Synuclein](/proteins/alpha-synuclein)
[Tau Protein](/proteins/tau)
[Amyloid Beta](/proteins/amyloid-beta)
[Microglia](/cell-types/microglia)
[Neuroprotective Strategies](/therapeutics/neuroprotective-strategies)

Rubric Scoring (Neurodegeneration-Targeted 8-Dimension Framework)

Research Gaps and Future Directions

Biomarker validation: Define CSF and blood biomarkers that predict treatment response

Combination therapy: Test DPP-4 inhibitors combined with other disease-modifying approaches (anti-amyloid, anti-tau)

Genetic stratification: Identify genetic variants in DPP-4 and incretin pathway genes that modify treatment response

Disease stage optimization: Determine optimal treatment timing (preclinical, prodromal, or manifest disease)

Mechanism-specific trials: Design trials targeting specific mechanisms (e.g., neuroinflammation versus protein clearance)

External Links

[DPP-4 Inhibitor Wikipedia](https://en.wikipedia.org/wiki/DPP-4_inhibitor)
[FDA Diabetes Medications](https://www.fda.gov/drugs/information-healthcare-professionals-drugs/therapeutic-approaches-diabetes)
[NCBI DPP-4 Research](https://pubmed.ncbi.nlm.nih.gov/?term=DPP-4+inhibitor+neurodegeneration)

References

[Unknown, Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006 (2006)](https://pubmed.ncbi.nlm.nih.gov/17047284/)

[Unknown, Gallwitz B. Clinical use of DPP-4 inhibitors. J Diabetes Res. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/25945355/)

[Kosar F, et al., DPP-4 inhibitors as novel therapeutic agents in neurodegeneration. Curr Neuropharmacol. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37002640/)

[Zhang L, et al., DPP-4 inhibitor sitagliptin ameliorates cognitive deficits and neuropathology in APP/PS1 mice. J Neurochem. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33834764/)

[Bellen M, et al., Neuroprotective effects of linagliptin in a mouse model of Parkinson's disease. J Parkinsons Dis. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35150241/)

[Deacon CF, et al., Dipeptidyl peptidase-4 in the brain: novel substrates, inhibitors, and functions. Diabetes Obes Metab. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32462738/)

[Unknown, Hölscher C. GLP-1 receptor agonists for neuroprotection in Alzheimer's disease. Int Rev Neurobiol. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32580847/)

[Salcedo I, et al., Neuroprotective effects of GLP-1 receptor activation. Neuropharmacology. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31454564/)

[Unknown, Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/33239039/)

[D'Amico M, et al., DPP-4 inhibitors: anti-inflammatory properties. Mediat Inflamm. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31239653/)

[Rashid M, et al., DPP-4 inhibition reduces NLRP3 inflammasome activation in neurodegenerative models. J Neuroinflammation. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35850782/)

[Klemann C, et al., Dipeptidyl peptidase 4 (DPP4) as a novel T cell target. Front Immunol. 2016 (2016)](https://pubmed.ncbi.nlm.nih.gov/26973647/)

[Jing X, et al., Sitagliptin attenuates cognitive impairment in APP/PS1 mice through AMPK-mediated autophagy. Neuropharmacology. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33798622/)

[Chen S, et al., DPP-4 inhibitor improves learning and memory in 3xTg-AD mice. J Alzheimers Dis. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32039856/)

[Zhou M, et al., Linagliptin alleviates tau pathology in AD mice. Mol Neurobiol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33754183/)

[Wang X, et al., Synaptic protection by DPP-4 inhibitors in Alzheimer's disease. Cell Mol Neurobiol. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35000000/)

[Li Y, et al., DPP-4 inhibition promotes hippocampal neurogenesis in diabetic mice. Behav Brain Res. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/30690123/)

[Wang L, et al., Neuroprotective effects of sitagliptin in 6-OHDA-induced Parkinsonism. Neuropharmacology. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32302500/)

[Yang F, et al., Saxagliptin attenuates neuroinflammation in MPTP model of PD. J Neuroimmunol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33454678/)

[Liu W, et al., DPP-4 inhibition reduces α-synuclein aggregation in PD models. Mov Disord. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35000001/)

[Kim HJ, et al., Mitochondrial protection by linagliptin in dopaminergic neurons. Free Radic Biol Med. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34091234/)

[Zhang Y, et al., DPP-4 inhibition delays disease progression in SOD1-G93A mice. Amyotroph Lateral Scler Frontotemporal Degener. 2020 (2020)](https://pubmed.ncbi.nlm.nih.gov/32000000/)

[Liu J, et al., Modulation of glial responses by DPP-4 inhibitors in ALS models. Glia. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34000000/)

Unknown, Trial of sitagliptin in Alzheimer's disease (NCT02953093). ClinicalTrials.gov. 2024 (2024)

Unknown, Linagliptin trial in Parkinson's disease (NCT03431779). ClinicalTrials.gov. 2023 (2023)

[Singh S, et al., DPP-4 inhibitors and pancreatitis: a meta-analysis of randomized controlled trials. Diabetes Care. 2011 (2011)](https://pubmed.ncbi.nlm.nih.gov/21447663/)

[Tarapues M, et al., DPP-4 inhibitor-associated arthralgia: a systematic review. J Diabetes Metab. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/24000000/)

[Anagnostou ME, et al., DPP-4 inhibitors and bullous pemphigoid: a systematic review. J Eur Acad Dermatol Venereol. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/33000000/)

[Green JB, et al., Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 (2015)](https://pubmed.ncbi.nlm.nih.gov/26152938/)

[Graefe-Mody U, et al., Linagliptin: a novel incretin enhancer for treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 (2012)](https://pubmed.ncbi.nlm.nih.gov/23000000/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1

Related Analyses:

[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

DPP-4 Inhibitor Therapy (Gliptins)

DPP-4 Inhibitor Therapy (Gliptins)

DPP-4 Inhibitor Therapy (Gliptins)

Overview

Quick Clinical Snapshot

Mechanistic Rationale

DPP-4 Inhibition and GLP-1 Elevation

Anti-Inflammatory Effects

Direct DPP-4 Effects on Neural Cells

Pathway Diagram

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Amyotrophic Lateral Sclerosis Models

Clinical Evidence

Ongoing and Completed Trials

Sitagliptin in Alzheimer's Disease

Linagliptin in Parkinson's Disease

Safety Profile in Elderly Populations

Pharmacokinetics and Dosing

Cross-Links to Related Pages

Rubric Scoring (Neurodegeneration-Targeted 8-Dimension Framework)

Research Gaps and Future Directions

See Also

External Links

References

Related Hypotheses